Mumbai, Aug. 13 -- Revenue from operations slumped 30.47% YoY to Rs 386.19 crore in the quarter ended 30 June 2025.
Profit before tax (PBT) stood at Rs 65.45 crore in Q1 FY26, down 11.16% from Rs 73.68 crore in the same period last year.
Total expenses fell 33.77% to Rs 320.54 crore in Q1 FY26, compared to Rs 484.03 crore in Q1 FY25. The cost of materials consumed stood at Rs 191.42 crore (down 8.05% YoY), employee benefit expenses were Rs 41.26 crore (up 5.17% YoY), and finance costs stood at Rs 6.79 crore (up 40.57% YoY) during the period under review.
EBITDA declined 1.24% YoY to Rs 95.30 crore in Q1 FY26. However, the EBITDA margin improved to 24.68% in Q1 FY26, up from 17.37% in Q1 FY25.
Aarti Pharmalabs (APL) is an established, ...
Click here to read full article from source
To read the full article or to get the complete feed from this publication, please
Contact Us.